{
    "clinical_study": {
        "@rank": "68992", 
        "arm_group": [
            {
                "arm_group_label": "AMA0076 0.1%", 
                "arm_group_type": "Experimental", 
                "description": "Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio."
            }, 
            {
                "arm_group_label": "AMA0076 0.25%", 
                "arm_group_type": "Experimental", 
                "description": "Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio."
            }, 
            {
                "arm_group_label": "AMA0076 0.50%", 
                "arm_group_type": "Experimental", 
                "description": "Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio."
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this parallel group study is to evaluate the safety, tolerability and\n      efficacy of AMA0076 in reduction of intraocular pressure in subjects with primary open-angle\n      glaucoma or ocular hypertension."
        }, 
        "brief_title": "Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Glaucoma", 
            "Ocular Hypertension", 
            "Eye Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Eye Diseases", 
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults 30-85 years of age.\n\n          -  Diagnosis of either POAG or OHT in both eyes.\n\n          -  Not receiving medication for IOP, or able to stop such medication for a washout\n             period and the duration of the study without significant risk of adverse consequences\n             related to glaucomatous disease.\n\n          -  Elevated IOP (\u2265 24 and \u2264 33 mm Hg at 8 AM and \u2265 21 and \u2264 33 mm Hg at 10 AM on\n             Screening Two visit and Baseline visit in one or both eyes off treatment [after a\n             washout phase in those subjects who were receiving ocular hypotensive therapy]).\n\n        Exclusion Criteria:\n\n        Ophthalmic exclusion criteria:\n\n          -  Uncontrolled intraocular hypertension defined as > 33 mm Hg in either eye at either\n             of the screening/baseline visits (after a washout phase in those subjects who were\n             currently receiving ocular hypotensive therapy).\n\n          -  Receiving more than one medication for IOP in either eye at time of screening.\n\n          -  Abnormal central corneal thickness.\n\n          -  BCVA worse than 20/200 (logMAR 1.0) in either eye\n\n          -  Significant visual field loss.\n\n          -  Acute angle-closure glaucoma or appositional or very narrow anterior chamber angle in\n             either eye."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02136940", 
            "org_study_id": "AMA0076-S-202"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "AMA0076 0.1%", 
                    "AMA0076 0.25%", 
                    "AMA0076 0.50%"
                ], 
                "intervention_name": "AMA0076", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 9, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Artesia", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Artesia Clinical - Site 11"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Inglewood", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Inglewood Clinical Site - Site 15"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Petaluma", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Petaluma Clinical Site - Site 17"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Morrow", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "Morrow Clinical Site - Site13"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roswell", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "Roswell Clinical Site - Site 18"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Rochester Clinical Site - Site 12"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Slingerlands", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Slingerlands Clinical Site - Site 19"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "Charlotte Clinical Site - Site 14"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "High Point", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "High Point Clinical Site - Site 16"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 2a, Multicenter, Randomized, Double-masked, Placebo-controlled, Parallel-group Study of AMA0076 in Topical Ocular Formulation for Safety, Tolerability and Efficacy in Reduction of Intraocular Pressure in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension", 
        "overall_contact": {
            "last_name": "John P Hall", 
            "phone": "7325566055"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mean change from baseline in mean diurnal intraocular pressure", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02136940"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean, mean change and percent change from baseline in intraocular pressure in both mean diurnal intraocular pressure and intraocular pressure at equivalent diurnal time points.", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Evaluation of safety variables including eye exam findings (best corrected visual acuity, biomicroscopy [including grading of conjunctival hyperemia], dilated fundus examination) adverse events, discontinuations due to adverse events, serious adverse events, and vital signs.", 
                "measure": "Compare the safety and tolerability of topically administered AMA0076 compared to vehicle, by evaluation of safety variables", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "Amakem, NV", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amakem, NV", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}